Skip to main content
AVLS Congress and UIP 2023 World Congress Main banner
Final Program


Conference Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Stream Session
Live Stream Session
Ticketed Event
Ticketed Event
Invitation Only
Invitation Only
Translation
Translation
Recorded Content
Recorded Content
CME
CME
Non-CME
Non-CME
Back

Fedor Lurie, MD, PhD (he/him/his)

UIP Research Chair
Jobst Vascular Institute
University of Michigan
Toledo, Ohio, United States

Dr. Lurie started his career as an academic vascular surgeon in 1980. He served as the faculty at the Urals Medical Academy (Russia), University of California Davis, and the University of Hawaii. He currently is the Associate Director of the Jobst Vascular Institute and Adjunct Research Professor at the University of Michigan Ann Arbor. Dr. Lurie’s main clinical and research interests are venous and lymphatic diseases, venous physiology, and clinical imaging. He serves as the Director of the American Board of Venous and Lymphatic Medicine, Director of the Vein Center Accreditation Board of the Intersocietal Accreditation Commission, and member of the Medicare Evidence Development & Coverage Advisory Committee.
Dr. Lurie is the Past President of the American venous forum, and the American venous forum Foundation, member of several committees of the Society for Vascular Surgery, an Honorary Member of the European venous Forum, and several European national vascular Surgery societies. He served as the principle investigator on eighteen multi-center clinical trials, published more than 160 original papers, multiple invited commentaries and review articles, and 17 book chapters. He is also an accomplished speaker with more than 200 presentations nationally and internationally.

Disclosure(s):

The forementioned Program Planner, Faculty, Author, Moderator, or Speaker, has declared for this educational activity, having no relevant financial relationship(s) with ineligible companies to disclose.

Presentation(s):